Holen Sie sich die Stockscreener-App
9.74
5.25%
-0.54
Handel nachbörslich:
9.63
-0.11
-1.13%
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
Mink Therapeutics Inc expected to post a loss of 82 cents a shareEarnings Preview - TradingView
Why Did INKT Stock Jump 30% Today? - Stocktwits
MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is MiNK Therapeutics Stock Trading Lower On Wednesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MiNK Therapeutics Stock Gains Amid New Market Developments - StocksToTrade
MiNK Therapeutics jumps on pediatric cancer collaboration and non-dilutive funding news - Quiver Quantitative
Key Patent Dispute Hits INKT’s Financials - timothysykes.com
MiNK Therapeutics (INKT) Stock Rockets 80% on Pediatric Cancer Partnership with C-Further - parameter.io
MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally - Benzinga
MiNK Therapeutics (INKT) Stock Rockets 80% Following Pediatric Cancer Partnership - Blockonomi
MiNK Therapeutics (INKT) Stock Surges 80% on C-Further Pediatric Cancer Deal - CoinCentral
Mink Therapeutics and C-Further Collaborate to Advance Prame-Targeted Inkt Cell Therapy for Pediatric Cancers - marketscreener.com
MiNK Therapeutics stock soars 80% on C-Further collaboration By Investing.com - Investing.com Canada
MiNK Therapeutics shares surged 70% in pre-market trading after the company announced that its partner C-Further received up to $1.1 million in funding to advance pediatric cancer cell therapy research. - Bitget
Why Did INKT Stock Surge 70% In Pre-Market Today? - Asianet Newsable
MiNK Therapeutics announces collaboration with C-Further to advance PRAME-targeted iNKT cell therapy - marketscreener.com
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers - Yahoo Finance
New off-the-shelf cell therapy targets aggressive childhood cancers - Stock Titan
MiNK Therapeutics (NASDAQ:INKT) Trading Up 1.7% – Time to Buy? - Defense World
MiNK Therapeutics (INKT) Projected to Post Earnings on Tuesday - Defense World
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Bond Watch: What is MiNK Therapeutics Incs revenue forecast2026 Volume & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - BioSpace
MiNK Therapeutics (INKT) director sells 500 shares in open trades - Stock Titan
The Technical Signals Behind (INKT) That Institutions Follow - Stock Traders Daily
INKT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
INKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
INKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
INKT Technical Analysis & ETF Price Forecast - Intellectia AI
Volume Summary: How does MiNK Therapeutics Inc correlate with Nasdaq2025 Biggest Moves & Community Shared Stock Ideas - baoquankhu1.vn
Precision Trading with Mink Therapeutics Inc. (INKT) Risk Zones - Stock Traders Daily
Published on: 2026-02-18 15:43:58 - baoquankhu1.vn
Downgrade Watch: What are GAN Limiteds technical support levelsEarnings Overview Summary & Growth Focused Entry Reports - baoquankhu1.vn
What is the fair value of MiNK Therapeutics Inc. stock nowQuarterly Trade Summary & Consistent Growth Equity Picks - mfd.ru
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of “Hold” from Brokerages - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Sectors: Can ZEOWW sustain its profitabilityQuarterly Profit Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Published on: 2026-02-12 21:29:01 - mfd.ru
Can MiNK Therapeutics Inc. maintain its current growth rateJuly 2025 News Drivers & Fast Gain Stock Tips - mfd.ru
Short Covering: Is MiNK Therapeutics Inc a defensive stockWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
What is MiNK Therapeutics Inc. s revenue forecastTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
MiNK Therapeutics (NASDAQ:INKT) Stock Price Up 1.6% – Here’s Why - Defense World
Technical Reactions to INKT Trends in Macro Strategies - Stock Traders Daily
MiNK Therapeutics Presents Data Supporting Allo-iNKT Cell Therapy In IPF At Keystone Symposia - Nasdaq
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - Investing News Network
MiNK Therapeutics Reports Preclinical Data Showing Anti-Fibrotic Effects of Allo-iNKT Cell Therapy for Idiopathic Pulmonary Fibrosis - geneonline.com
MiNK Therapeutics Presents New Data of allo-iNKT Cell - GlobeNewswire
New IPF lung data: key immune cells depleted in advanced disease - Stock Titan
Published on: 2026-02-03 22:53:59 - baoquankhu1.vn
Trading the Move, Not the Narrative: (INKT) Edition - Stock Traders Daily
Agenus (AGEN) Q2 2025 Earnings Call Transcript - The Globe and Mail
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to “Hold” - Defense World
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):